INTRODUCTION
Opioids are used for moderate to severe pain caused by cancer [1] , trauma, and operations. Opioid therapy may be considered in combination with non-pharmacological and non-opioid therapies for selected patients suffering from severe nonmalignant persistent pain [2] . However, treatment with potent opioids is connected with frequent and problematic side effects [3] . One of the most common side effects is opioid-induced constipation (OIC). In a publication based on patient data from a Swedish noninterventional study, the conclusion was that OIC is a costly complication that also affects the quality of life (QoL) of patients. The complication may also limit effective pain therapy [4] .
Oxycodone/naloxone is an opioid analgesic combined with an opioid antagonist in a fixed prolonged-release combination which has been shown to significantly reduce opioid-induced constipation while providing effective analgesia in patients with moderate to severe non-malignant pain [5] . Oxycodone/naloxone has also been confirmed to be well tolerated and efficacious in patients suffering from moderate to severe cancer pain [6] . The objective of the observational study was to compare health-related QoL (HRQoL), healthcare resource use, and costs in patients with severe pain, treated with oxycodone and laxatives, who were subsequently switched to treatment with oxycodone/naloxone.
METHODS
The study (OXN9513 GAIN) was an observational study of patients with severe pain treated with opioids in Sweden. Patients treated with oxycodone in a stable, adequate dose and time period with symptoms of OIC despite laxatives were enrolled in the study. The participating patients served as their own controls, and data for comparison were therefore collected retrospectively before the initiation of oxycodone/naloxone treatment and after initiation of treatment with oxycodone/naloxone. The prescription of oxycodone/naloxone was clearly separated from the decision to include the patient in the study.
The observational study consisted of two visits, i.e., before (visit 1) and after (visit 2) the initiation of oxycodone/naloxone treatment, covering a total period of 8 weeks, as illustrated in Fig. 1 
Compliance with Ethics Guidelines
Ethical approval for the study was obtained by Table 2 .
The total number of visits to caregivers and telephone contacts was higher in the 4-week period before the initiation of oxycodone/naloxone treatment than in the (Table 3) .
Few patients had been hospitalized due to pain or constipation during the 4 weeks immediately preceding each visit. In total, two patients had spent 11 days (4 and 7 days, respectively) in hospital during the 4 weeks immediately preceding the initiation of oxycodone/naloxone treatment, and two patients had spent 8 days (4 days each) in hospital during the 4 weeks immediately following the initiation of oxycodone/naloxone.
The mean dose of oxycodone/naloxone was 39.2 mg/day, and the daily doses of oxycodone varied between 10 and 80 mg. Since some patients had dose adjustments during the study period (n = 3), the mean dose was calculated as a weighted mean based on the number of days with a specific dose. The dosage of oxycodone in the participating patients ranged from low to moderate, corresponding to approximately 15-120 mg MED (morphine equivalents per day) [13] . High-dose opioid therapy has been defined as [200 mg MED [14] , although a recent guideline considers a MED of [90 mg to be a high dose [2] .
After the initiation of oxycodone/naloxone treatment the patients were asked to score their global impression of pain relief (global impression of oxycodone/naloxone), ranging from 1 (very poor) to 5 (very good). For the majority of the responding patients the impression of pain relief was good to very good. Total number of patients: 37. Data in table are presented as the number of visits/calls a The observational study consisted of two visits, i.e., before (visit 1) and after (visit 2) the initiation of oxycodone/naloxone treatment, covering a total period of 8 weeks (4 weeks before the initiation of treatment and 4 weeks thereafter)
Purchases of laxatives were higher before the initiation of oxycodone/naloxone treatment, with 23 patients reporting that they had bought laxatives, than after the initiation of oxycodone/naloxone treatment, with ten patients reporting such purchases.
No patients in the study had any full-time employment, and only three patients reported part-time employment. A majority of the patients reported that they were retired or have had an early retirement. Several of the patients indicated that they were on long-term sick leave.
Both HRQoL measured with the EQ-5D
instrument and experience of pain intensity EQ-VAS showed improvements after the initiation of oxycodone/naloxone, although the differences were not statistically significant. The improvements measured by the disease-specific instruments PAC-QoL, PAC-SYM, and BFI were all statistically significant ( Table 4 ).
The direct costs per patient during each of the 4-week periods preceding visits 1 and 2, respectively, covering resource utilization associated with treatment of OIC, with the exception of costs for analgesics and prescribed laxatives, are presented in Table 5 . In general, the costs for the 4-week period after oxycodone/naloxone had been prescribed were ('not at all' or 'none of the time') to 4 ('extremely' or 'all of the time'), with a maximum value of 96 d PAC-QoL instrument: satisfaction index scores range from 0 ('not at all' or 'none of the time') to 4 ('extremely' or 'all of the time'), with a maximum value of 16 e Patient Assessment of Constipation Symptoms (PAC-SYM) instrument: scores range from 0 ('absence of symptoms') to 4 ('very severe symptom'), with a maximum value of 48 f Bowel Function Index (BFI) where 0 is equal to 'no problems' and 100 is equal to 'most severe problems' g Mean pain intensity scores range from 0 ('no pain') to 10 (worst pain imaginable') h The number of patients that have values both at visit 1 and visit 2 lower than those for the initial 4-week period when patients had been treated with oxycodone and laxatives. The total difference (EUR100.36, over 28 days) between the two 4-week periods corresponds to an average cost-saving of EUR3.58/day. In comparison, the average daily cost of oxycodone/naloxone was EUR2.32, corresponding to a net cost-saving of EUR1.26 per day. In addition, the daily cost of oxycodone and laxatives in the first 4 weeks of the study period (preceding visit 1) should also be considered in order to estimate the total cost-savings.
Costs related to adverse events were not estimated because most adverse events reported were not related to treatment of pain or OIC.
Indirect costs related to productivity losses for patients who could not work due to problems with constipation were not calculated because no patient indicated that they had any full-time employment and only three patients had part-time employment. In addition, the mean age was high, such that 62% of the patients were retired. Also, several patients had malignant diseases, which probably was the reason for not working.
DISCUSSION
The results of our analysis show that in the 4 weeks immediately after the patients had [16] and that oxycodone/naloxone is a cost-effective option for treating patients with severe pain and OIC [17, 18] .
One limitation of the cost calculation in this study is that the costs of drugs prescribed during the 4-week period before the initiation of the oxycodone/naloxone treatment were not included. The reason for not including these data is that a large variety of different types of drugs and doses were reported for this time interval. Nevertheless, the cost calculation shows that treatment with oxycodone/naloxone in the analyzed patient population was cost-saving even when only including costs for hospitalization, healthcare contacts and over-the-counter purchases of laxatives. Adding the costs for prescribed drugs for the period before the initiation of oxycodone/naloxone treatment would yield an even larger cost-saving.
In spite of the high occurrence of OIC, inclusion of patients proved to be very difficult. One reason for this may be that the majority of patients referred to the participating centers had multiple medical and other problems that either excluded them from the study or, if the patients were eligible, led them to decline to participate. The main drawback of the study is the limited number of patients available for analysis. It was therefore not meaningful to perform additional statistical analyses.
CONCLUSION
The most notable conclusion which can be drawn from our results is that the oxycodone/naloxone treatment appeared to 
